Elastography Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Elastography Imaging Market Trends and Insights

Rising incidence of chronic diseases & breast cancer

Escalating metabolic-dysfunction-associated steatotic liver disease prevalence drives routine liver stiffness measurement adoption, where two-dimensional shear-wave elastography achieves 94% accuracy at a 14.4 kPa cutoff ^{[1]Armandi, A. et al., “Liver Stiffness Cutoff of 14.4 kPa Detects Advanced Fibrosis with 94% Accuracy,” BMC Gastroenterology, bmcgastroenterology.biomedcentral.com}. Combining ultrasound-guided attenuation parameters with shear-wave data stratifies MASLD patients by life-threatening event risk. Breast elastography now supports dense-breast screening, distinguishing malignant microcalcifications with 88% sensitivity and 86.7% specificity at a 62 kPa threshold. Growing oncology adoption bolsters equipment utilization in radiology suites. The dual-organ demand profile solidifies elastography as a preferred non-invasive alternative to biopsy.

Shift toward minimally invasive surgeries

Shear-wave elastography predicts rotator-cuff tendon quality before repair, enabling surgeons to tailor operative strategy more accurately. Robotic systems incorporate 3-D ARFI imaging to guide prostate procedures with agreement levels comparable to multiparametric MRI. AI-enhanced elastography automatically pinpoints biopsy targets, lowering sampling errors and procedure times. Strategic acquisitions, such as Hologic’s USD 350 million Sonata buy-out, highlight the commercial appeal of ultrasound-guided, fibroid-specific minimally invasive platforms. The technology’s intraoperative role is widening from liver to musculoskeletal and gynecological interventions.

Adoption of elastography for NASH-related fibrosis staging

FDA approval of Resmetirom accelerated vibration-controlled transient elastography uptake for therapy monitoring. Studies combining the ELF test with elastography deliver an AUROC of 0.829 for advanced fibrosis detection, outperforming biochemical markers. Two-dimensional shear-wave imaging attains 100% sensitivity for significant fibrosis at a 7 kPa threshold, providing cost-effective alternatives to MR elastography. Samsung’s S-Shearwave Imaging shows 0.94 diagnostic accuracy for advanced fibrosis in biopsy-controlled trials. The ability to measure liver stiffness and steatosis simultaneously underpins comprehensive NASH management pathways.

AI-enabled point-of-care ultrasound elastography

Siemens Healthineers’ Auto Point functionality cuts liver exam time by 75% without compromising accuracy. Philips Auto ElastQ reaches 99% measurement reproducibility and shortens study duration by 60%. AI-guided novice echocardiography improves correct view acquisition rates to 88% versus 76% with conventional techniques. GE HealthCare and NVIDIA collaborate on autonomous ultrasound, signaling a pipeline for fully automated elastography data acquisition. AI deepens standardization, expanding eligibility beyond specialized imaging centers.

Unfavorable reimbursement frameworks

Medicare restricts CPT 76981/76982 coverage to advanced hepatic fibrosis in defined chronic liver diseases, limiting broader screening uses. Aetna deems elastography investigational outside liver applications, stalling cardiology and musculoskeletal reimbursement. Prior-authorization hurdles lengthen administrative cycles and discourage routine ordering. The absence of standardized payment for cardiac elastography delays guideline endorsements. Evidence-based coverage expansions are expected only after large-scale outcome studies demonstrate cost savings.

High capital cost of MRI-based systems

Full-body MR elastography platforms require USD 1.5–3 million outlays, burdening smaller centers ^{[2]RSNA, “Economic Analysis of MR Elastography,” radiology.rsna.org} . Yet two-dimensional shear-wave systems match diagnostic performance for significant fibrosis at a fraction of that cost. Operational complexity demands specialized technologists and dedicated scanner time slots. Limited availability extends patient wait times in hepatology clinics. Emerging handheld ultrasound devices under USD 4,000, like Butterfly iQ3, intensify cost pressure on premium MR options.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Modality: Ultrasound Dominance Drives Clinical Integration

Ultrasound elastography captured 62.30% revenue in 2025, reflecting superior workflow integration and lower cost relative to MR platforms. That share equates to USD 2.97 billion of the elastography imaging market size in 2025. MR elastography advances at a 7.19% CAGR, underpinned by gold-standard accuracy for fibrosis staging, but uptake is limited to tertiary centers due to high acquisition costs. Continuous R&D delivers conformable ultrasound electronics for non-planar monitoring, while AI automation enhances repeatability across operator skill levels.

MR elastography’s precision sustains demand in complex hepatology practices, yet capital barriers spur hybrid purchasing strategies where ultrasound handles routine follow-up and MR is reserved for equivocal cases. Equipment vendors integrate AI reconstruction to shorten MR scan times and reduce per-exam cost. The balancing act between clinical gold-standard status and economic realities shapes long-term modality mix.

By Technology Type: Shear-Wave Precision Meets Strain Accessibility

Shear-wave techniques represented 45.10% of 2025 sales, underlining their quantitative advantage and lower operator bias. Strain elastography’s 7.55% CAGR owes to software upgrades that convert existing scanners at minimal cost—a value proposition compelling in community hospitals. The elastography imaging market share leadership of shear-wave is reinforced by guideline endorsements for liver fibrosis and thyroid nodule assessment.

Transient elastography holds a niche in NASH monitoring, whereas ARFI benefits interventional radiology by providing real-time stiffness cues during needle placement. Hybrid solutions that fuse shear-wave with ARFI emerge to satisfy oncology procedural guidance. Diagnostic performance gains from machine-learning-based stiffness estimation continue to blur boundaries among technology types.

By Imaging Technique: 2-D Efficiency Versus 3-D Innovation

Two-dimensional elastography commanded 65.05% revenue in 2025, favored for high-throughput examinations. Three-dimensional and four-dimensional formats are projected at 7.02% CAGR as volumetric analysis proves valuable for complex lesions and cardiac mechanics. Portable devices such as Butterfly iQ3 introduce 3-D fan-sweep modes, accelerating democratization of advanced imaging.

Real-time 4-D elastography enhances myocardial strain assessment, aiding early heart-failure detection. Flexible polymer ultrasound arrays now enable 3-D elastography on curved anatomy like knees and neonatal heads, opening new research avenues. The interplay of computational cost and diagnostic yield drives site-specific adoption decisions.

By Portability: Cart Systems Stability Amid Handheld Disruption

Cart systems consolidated 70.55% revenue in 2025. Multi-transducer support and higher computing power keep them indispensable for multi-specialty hospitals. Yet handheld devices expand at 7.79% CAGR, propelled by emergency medicine, critical care, and rural outreach programs. Handheld unit shipments exceed 30% of total ultrasound volumes in several Southeast Asian markets.

Cloud-connected handhelds facilitate remote mentorship and AI post-processing, further eroding historical performance gaps versus cart consoles. Enterprise imaging networks are integrating handheld data to maintain consistent reporting formats, easing credentialing concerns. As price points fall, secondary and primary care sites become first-time elastography purchasers.

By Application: Radiology Leadership Amid Cardiology Acceleration

Radiology retained 38.10% share in 2025, equal to USD 1.82 billion of the elastography imaging market. Cardiology, at an 8.02% CAGR, accelerates on the back of AI-guided strain protocols that simplify novice scans. Heart-failure programs adopt left-ventricular stiffness metrics for risk stratification, supporting reimbursement petitions.

Urology applications capitalize on 3-D ARFI to localize prostate lesions while reducing biopsy core counts. Vascular elastography evaluates carotid plaque stability, augmenting Doppler findings to refine intervention decisions. Obstetrics & gynecology extend use into fibroid therapy guidance post Hologic-Gynesonics transaction, marking cross-disciplinary fertilization.

By End-User: Hospital Dominance Amid Outpatient Expansion

Hospitals generated 68.10% of 2025 spending, reflecting their need for comprehensive imaging suites and multidisciplinary usage. Ambulatory surgical centers grow at 7.60% CAGR as reimbursement incentivizes outpatient liver and thyroid biopsy services. Diagnostic imaging centers integrate ultrasound elastography into routine abdominal studies to differentiate simple steatosis from progressive fibrosis.

Specialty clinics such as hepatology and cardiology see rising elastography adoption to monitor chronic conditions within their own settings, reducing patient referrals and improving retention. Point-of-care programs in emergency departments address trauma and sepsis triage with quick stiffness evaluations that flag occult organ injury.

Geography Analysis

North America dominated revenue with a 40.75% share in 2025. Favorable reimbursement for liver elastography and rapid AI software clearance create a receptive regulatory environment. The United States initiated multi-center trials measuring elastography endpoints in NASH drug development, anchoring demand among hepatologists.

Europe maintains stable adoption as national health systems emphasize cost-effectiveness; portable devices offer lower total cost of ownership for district hospitals. The region’s imaging societies publish harmonized protocols, improving cross-country comparability and vendor neutrality.

Asia-Pacific delivers an 8.12% CAGR, fueled by expanding healthcare spending, large diabetic populations, and domestic manufacturing of affordable ultrasound chips. China’s NMPA issued updated Class III imaging guidelines in 2024, expediting domestic product registrations and spurring local competition. India’s point-of-care programs incorporate handheld elastography to screen fatty-liver disease in primary care.

The Middle East and Africa witness incremental adoption through private hospital groups investing in premium diagnostic services. South America shows steady growth as public health campaigns emphasize non-invasive cirrhosis detection, particularly in Brazil and Argentina.

Regulatory Landscape

Elastography imaging systems and related software are regulated primarily as medical devices. In the United States, ultrasound-based elastography functions and upgrades are commonly pursued through the FDA 510(k) pathway. Recent clearances show ongoing predicate-based commercialization for elastography capabilities, including Sonic Incytes Velacur (510(k) K233977, September 2024) and Quality Electrodynamics SureWave Elastography (510(k) K242006, February 2025), supporting routes for both hardware and software-enabled stiffness quantification.

In Europe, manufacturers operate under the Medical Device Regulation (MDR), where alignment to harmonized standards supports presumption of conformity for safety and performance of electrically powered systems. In June 2026, the Official Journal of the European Union updated the MDR harmonized standards list, including EN 60601-1:2006/A13:2024, which increases the emphasis on maintaining current test evidence and technical documentation. Discussions aimed at reducing MDR/IVDR burden (including a 2025 proposal referenced by EU bodies) also factor into compliance planning for vendors with broad ultrasound portfolios.

Value Chain Analysis

The elastography imaging value chain covers (i) component inputs (ultrasound transducers and materials, beamforming and signal-processing electronics, and compute hardware for on-device or cloud inference), (ii) system integration (cart and handheld ultrasound platforms and, separately, MR elastography ecosystems), (iii) software development and validation (stiffness quantification, automation, and workflow tools), and (iv) downstream distribution through direct hospital sales, channel partners, and procurement pathways such as GPO-linked contracting in the United States. Market dynamics in this report are shaped by the installed base of ultrasound systems, which accounts for 62.30% of 2025 revenue for the ultrasound modality, and can be expanded through software and compatible probe offerings. This supports faster commercialization cycles than capital-intensive MR deployments.

Key friction points remain upstream and compliance-related. Supply-chain shortages of high-frequency piezo crystals constrain probe availability, while AI-assisted stiffness mapping increases documentation, validation, and post-market monitoring requirements under regimes such as EU MDR. Manufacturers also manage concentration risks in specialized modules, for example ARFI-related capabilities, and in validated algorithms that must be maintained across software revisions without disrupting performance claims. As a result, quality systems, verification testing, and long-term service agreements remain central to the value chain.

Market Opportunities and Future Outlook

A key whitespace is multiparametric liver assessment on portable and point-of-care platforms that combine stiffness with steatosis-related metrics in a single workflow. This approach improves clinical usefulness for MASLD/MASH pathways and follow-up monitoring. Recent FDA clearances support packaging in this direction, including Sonic Incytes Velacur ONE (August 2025) with AI-guided acquisition and added measurements such as attenuation and VDFF (Velacur Determined Fat Fraction), and E-Scopics Hepatoscope with expanded capabilities cleared in May 2026. These clearances create concrete commercial stepping stones for vendors to bundle elastography into broader liver disease management features, rather than positioning stiffness measurement strictly as a stand-alone add-on.

Standardization and automation also create near-term differentiation as purchasers prioritize reproducibility and reduced operator dependence. Alignment to recognized standards such as IEC 63412-1, referenced alongside newer device clearances, supports common performance language across sites and can simplify multi-site rollouts for hospital networks. Payer constraints remain a gating factor for non-liver indications, including policies that treat non-liver uses as investigational, which creates opportunity for vendors and clinical groups to focus evidence generation and workflow integration on reimbursed liver use-cases. That evidence base can then support expansion into cardiology and other applications.